Affordable Access

deepdyve-link
Publisher Website

Efficacy and safety of pharmacotherapies for smoking cessation in anxiety disorders: Subgroup analysis of the randomized, active- and placebo-controlled EAGLES trial.

Authors
  • Ayers, Catherine R1
  • Heffner, Jaimee L2
  • Russ, Cristina3
  • Lawrence, David3
  • McRae, Thomas3
  • Evins, A Eden4
  • Anthenelli, Robert M1
  • 1 Department of Psychiatry, University of California, San Diego, California.
  • 2 Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, Washington.
  • 3 Global Product Development, Pfizer, New York, New York.
  • 4 Center for Addiction Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts.
Type
Published Article
Journal
Depression and anxiety
Publication Date
Mar 01, 2020
Volume
37
Issue
3
Pages
247–260
Identifiers
DOI: 10.1002/da.22982
PMID: 31850603
Source
Medline
Keywords
Language
English
License
Unknown

Abstract

Smoking rates are high in adults with anxiety disorders (ADs), yet little is known about the safety and efficacy of smoking-cessation pharmacotherapies in this group. Post hoc analyses in 712 smokers with AD (posttraumatic stress disorder [PTSD], n = 192; generalized anxiety disorder [GAD], n = 243; panic disorder [PD], n = 277) and in a nonpsychiatric cohort (NPC; n = 4,028). Participants were randomly assigned to varenicline, bupropion, nicotine-replacement therapy (NRT), or placebo plus weekly smoking-cessation counseling for 12 weeks, with 12 weeks follow-up. General linear models were used to test the effects of treatment group, cohort, and their interaction on neuropsychiatric adverse events (NPSAEs), and continuous abstinence weeks 9-12 (treatment) and 9-24 (follow-up). NPSAE incidence for PTSD (6.9%), GAD (5.4%), and PD (6.2%) was higher versus NPC (2.1%), regardless of treatment. Across all treatments, smokers with PTSD (odds ratio [OR] = 0.58), GAD (OR = 0.72), and PD (OR = 0.53) had lower continuous abstinence rates weeks 9-12 (CAR9-12) versus NPC. Varenicline demonstrated superior efficacy to placebo in smokers with GAD and PD, respectively (OR = 4.53; 95% confidence interval [CI] = 1.20-17.10; and OR = 8.49; 95% CI = 1.57-45.78); NRT was superior to placebo in smokers with PD (OR = 7.42; 95% CI = 1.37-40.35). While there was no statistically significant effect of any treatment on CAR9-12 for smokers with PTSD, varenicline improved 7-day point prevalence abstinence at end of treatment in this subcohort. Individuals with ADs were more likely than those without psychiatric illness to experience moderate to severe NPSAEs during smoking-cessation attempts, regardless of treatment. While the study was not powered to evaluate abstinence outcomes with these subgroups of smokers with ADs, varenicline provided significant benefit for cessation in those with GAD and PD, while NRT provided significant benefit for those with PD. © 2019 The Authors. Depression and Anxiety Published by Wiley Periodicals, Inc.

Report this publication

Statistics

Seen <100 times